RecruitingNCT07101094

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)


Sponsor

Bristol-Myers Squibb

Enrollment

300 participants

Start Date

Sep 22, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Aged ≥18 years at index date.
  • Have a confirmed diagnosis of schizophrenia before index date.
  • Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
  • Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
  • Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).
  • English or Spanish speaking.

Exclusion Criteria2

  • Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
  • Evidence of use of XT prior to time of eligibility screening.

Interventions

DRUGxanomeline and trospium chloride (X/T) therapy

According to the product label


Locations(17)

Local Institution - 0009

Orange, California, United States

Lumos Clinical Research Center

San Jose, California, United States

Local Institution - 0003

Evanston, Illinois, United States

Local Institution - 0007

Baltimore, Maryland, United States

Local Institution - 0017

Bel Air, Maryland, United States

Local Institution - 0004

Catonsville, Maryland, United States

Local Institution - 0008

Belmont, Massachusetts, United States

Local Institution - 0002

Boston, Massachusetts, United States

Mayflower Clinical

South Dartmouth, Massachusetts, United States

Omaha Insomnia and Psychiatric Services

Omaha, Nebraska, United States

Hackensack Meridian Health - Carrier Clinic

Belle Mead, New Jersey, United States

Local Institution - 0015

New York, New York, United States

Local Institution - 0016

Kinston, North Carolina, United States

Local Institution - 0014

Westlake, Ohio, United States

Continuum Health Providers

Fort Mill, South Carolina, United States

Local Institution - 0012

El Paso, Texas, United States

Local Institution - 0013

Longview, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07101094


Related Trials